Doubts, cost cited for lack of urate-lowering therapy adherence among African-American gout patients
Singh JA. Arthritis Res Ther. 2014;doi:10.1186/ar4524.
Facilitators and barriers to high urate-lowering therapy adherence in African-American patients with gout, including drug effectiveness and cost, were identified in a recent study.
Researcher Jasvinder A. Singh, MD,MPH, department of medicine at the School of Medicine and Division of Epidemiology, University of Alabama, Birmingham, studied 43 African-American patients with gout (mean age, 63.9 years; 67% men) who participated in nine nominal groups, a variant on focus groups. The sessions lasted up 1.5 hours, with six focusing on patients with lowurate-lowering therapy (ULT) adherence and three centered on patients with high ULT adherence (medication possession rations of <0.80 or ≥0.80, respectively). Patients discussed and ranked their concerns, and qualitative analysis was conducted.
No hay comentarios:
Publicar un comentario